Scholarlink

<p>Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a poor prognosis. While the medicinal plant <i>Eclipta prostrata</i> has shown promising anticancer properties against AML, its underlying mechanisms against AML remain largely unexplored. Hence, this study aimed to unveil the molecular mechanisms of <i>E. prostrata</i>, identify therapeutic targets, detect regulatory elements, and discover potential biomarkers for AML using comprehensive <i>in-silico</i> analyses. We implemented an integrated computational approach combining network pharmacology, molecular docking, molecular dynamics simulations, 3D-QSAR modeling, gene regulatory network, gene expression, patient survival, and cancer hallmarks analysis to investigate the mechanism of action of <i>E. prostrata</i> against AML. Our computational approaches identified 12 potential anti-cancer compounds from <i>E. prostrata</i>. Molecular docking revealed strong binding affinities of Kaempferol (-8.931&#xa0;kcal/mol) and Apigenin (-8.752&#xa0;kcal/mol) to FLT3, compared to control Pacritinib (-5.403&#xa0;kcal/mol). Tricetin (-8.634&#xa0;kcal/mol) and Diosmetin (-7.780&#xa0;kcal/mol) showed strong binding to PIM1 compared to control SEL24 (-6.385&#xa0;kcal/mol). Post-molecular dynamics simulation MM-GBSA analysis further confirmed these interactions, with binding free energies for FLT3: Kaempferol (-73.75&#xa0;kcal/mol), Apigenin (-68.76&#xa0;kcal/mol), Pacritinib (-51.27&#xa0;kcal/mol); and for PIM1: Tricetin (-64.28&#xa0;kcal/mol), Diosmetin (-52.2&#xa0;kcal/mol), SEL24 (-53.38&#xa0;kcal/mol). Predicted IC<sub>50</sub> values showed promising results for PIM1 inhibition by Tricetin (406.44&#xa0;nM) and Diosmetin (523.60&#xa0;nM), and for FLT3 inhibition by Kaempferol (493.17&#xa0;nM) and Apigenin (588.84&#xa0;nM). The developed 3D-QSAR models showed robust predictive power (PIM1: R<sup>2</sup> = 0.96, Q<sup>2</sup> = 0.93; FLT3: R<sup>2</sup> = 0.95, Q<sup>2</sup> = 0.85). Key regulatory elements were identified, including microRNAs (hsa-mir-335-5p, hsa-mir-150-5p, has-mir-1324) and transcription factors (ABL1, RUNX1, SP1, PML) regulating the target genes. FLT3 and MPO were identified as specific diagnostic and prognostic biomarkers for AML. This comprehensive <i>in-silico</i> analysis revealed promising therapeutic compounds from <i>E. prostrata</i> targeting FLT3 and PIM1, along with novel biomarker potentials of FLT3 and MPO for improved AML diagnosis and prognosis, subject to further experimental validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In silico approaches unveil the mechanism of action of Eclipta prostrata against acute myeloid leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月26日

查看全文
  • K.M. Tanjida Islam,
  • Md. Muzahidul Islam,
  • Jisan Bin Habib,
  • Susen Sarker,
  • Azrin Ahmed,
  • Md Sohel,
  • Fahmida Tabassum,
  • Saborni Sarker,
  • Sheikh Abdullah Al Ashik,
  • Roksana Khanam,
  • Shahin Mahmud

摘要

Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a poor prognosis. While the medicinal plant Eclipta prostrata has shown promising anticancer properties against AML, its underlying mechanisms against AML remain largely unexplored. Hence, this study aimed to unveil the molecular mechanisms of E. prostrata, identify therapeutic targets, detect regulatory elements, and discover potential biomarkers for AML using comprehensive in-silico analyses. We implemented an integrated computational approach combining network pharmacology, molecular docking, molecular dynamics simulations, 3D-QSAR modeling, gene regulatory network, gene expression, patient survival, and cancer hallmarks analysis to investigate the mechanism of action of E. prostrata against AML. Our computational approaches identified 12 potential anti-cancer compounds from E. prostrata. Molecular docking revealed strong binding affinities of Kaempferol (-8.931 kcal/mol) and Apigenin (-8.752 kcal/mol) to FLT3, compared to control Pacritinib (-5.403 kcal/mol). Tricetin (-8.634 kcal/mol) and Diosmetin (-7.780 kcal/mol) showed strong binding to PIM1 compared to control SEL24 (-6.385 kcal/mol). Post-molecular dynamics simulation MM-GBSA analysis further confirmed these interactions, with binding free energies for FLT3: Kaempferol (-73.75 kcal/mol), Apigenin (-68.76 kcal/mol), Pacritinib (-51.27 kcal/mol); and for PIM1: Tricetin (-64.28 kcal/mol), Diosmetin (-52.2 kcal/mol), SEL24 (-53.38 kcal/mol). Predicted IC50 values showed promising results for PIM1 inhibition by Tricetin (406.44 nM) and Diosmetin (523.60 nM), and for FLT3 inhibition by Kaempferol (493.17 nM) and Apigenin (588.84 nM). The developed 3D-QSAR models showed robust predictive power (PIM1: R2 = 0.96, Q2 = 0.93; FLT3: R2 = 0.95, Q2 = 0.85). Key regulatory elements were identified, including microRNAs (hsa-mir-335-5p, hsa-mir-150-5p, has-mir-1324) and transcription factors (ABL1, RUNX1, SP1, PML) regulating the target genes. FLT3 and MPO were identified as specific diagnostic and prognostic biomarkers for AML. This comprehensive in-silico analysis revealed promising therapeutic compounds from E. prostrata targeting FLT3 and PIM1, along with novel biomarker potentials of FLT3 and MPO for improved AML diagnosis and prognosis, subject to further experimental validation.